| Development
Terminated |
| GW420867X/HBY1293 | GlaxoSmithKline | JAIDS
2000; also summer IAS meeting |
| ALX40-4C | Allelix Pharmaceuticals | Formulation difficulties, lack of efficacy |
| AMD3100 | AnorMed
Inc. | Cardiac arrhythmias
at high doses, lack of efficacy at low |
| PD-178390 | Parke-Davis | Casualty
of Pfizer merger |
| CI-1012 | Parke-Davis | Casualty
of Pfizer merger |
| PNU-142721 | Pharmacia & Upjohn | Casualty of P&U’s decision to leave HIV field |
| NSC 651016 | Pharmacia & Upjohn | Casualty of P&U’s decision to leave HIV field |
| UC781 | Biosyn Inc. | Being developed as topical microbicide |
| zintevir/AR-177 | Antigenics
(formerly Aronex) | Terminated subsequent to takeover and poor results |
| Clinical Hold |
| emtricitabine/FTC/Coviracil | Triangle/Abbott | Submission of NDA to be significantly delayed |
| (-)dOTC/BCH-10618/SPD754 | Shire
Pharmaceuticals PLC | Deaths in monkeys |
| capravirine/S-1153/AG-1549 | Agouron (Pfizer) | Vasculitis
in dogs may mean curtains for cap. |
| mozenavir/DMP-450 | DuPont
(now BMS) | Electro-cardiographic
abnormalities in animals |
| Glacial Development |
| Pentafuside/T-20 | Trimeris/Roche | 48-week results released; NDA to be filed 2nd half 2002 |
| T-1249 | Trimeris/Roche | Phase I; longer half-life may allow QD dosing |
| Late Pipeline |
| emivirine/MKC-442/Coactinon | Triangle/Abbott | Triangle hopes to file NDA by year end; ICAAC |
| Middle Pipeline |
| atazanavir/BMS-232632 | Bristol-Myers
Squibb | Moving slowly but
deliberately through phase II |
| tipranavir | Boehringer-Ingelheim | "Trinity of major obstacles,” paper at summer IAS |
| VX-175/GW433908 | Vertex/GlaxoSmithKline | Amprenavir
prodrug, PK dose-ranging at 8CROI |
| SCH-C | Schering/Praecis | Results of 8-week study presented at 9CROI |
| PRO 542 | Progenics Pharmaceuticals | Phase II, being
studied in combination with T-20 |
| DPC-083 | DuPont (now BMS) | Eyed
to hit market in 2003; paper at 7CROI |
| TMC-125 | Tibotec/Virco | "Amazing potency" unveiled at 9CROI; to file NDA 2004 |
| Deep Pipeline |
| dADP/amdoxovir | Triangle
Pharmaceuticals | Phase
I/II dose ranging study presented at 8CROI |
| TMC-120 | Tibotec/Virco | Paper at 8CROI |
| TMC-126 | Tibotec/Virco | Paper at 8CROI |
| DPC-961,
DPC-963 | DuPont (BMS) | Atazanavir may take priority over these |
| Calanolide-A | SarawakMed | Paper on this at 7CROI |
| GPG-NH2 | Tripep
AB/Karolinska Institute | Early activity
in humans not too impressive |
| SCH-D | Schering/Praecis | Follow-up compound to SCH-C |
| UK-427,857 | Pfizer | Said
to be moving into Phase I "soon” |
| DPC-681,
DPC-684 | DuPont (BMS) | Phase I studies on-going; paper
at 8CROI |
| AMD-3465, 8445, 8664 | AnorMed | AMD8664 is orally available analogue of AMD3100 |
| TAK-779 | Takeda
Pharmaceuticals | Being studied in combination with T-20 |
| HE2000 | Hollis-Eden Pharmaceuticals | Phase I/II enrolling in U.S.; info from company, other |
| PRO 140 | Progenics Pharmaceuticals | Moving into Phase I/II; press release |
| PRO 367 | Progenics Pharmaceuticals | Phase I recently
completed |
| Hu5A8 | Tanox
Biosystems, Inc. | Phase I clinical study began 8/1/01 |
| PEHRG214 | Virionyx | Phase
I at Boston Deaconess
Hospital, 3/01 |
| HIV NCp7 | Achillion Pharmaceuticals | Pre-clinical; also in Phase I
for HBV |
| SPD-756 | Shire Pharmaceuticals PLC | Formerly BCH-13520 |
| Fd4C/ACH-126,443 | Achillion
Pharmaceuticals | L. Dunkle on this,
but will it go the way of other ‘F’ drugs? |
| 5-helix | Howard
Hughes Medical Inst. | Science
2001, 291: 884-888 |
| ADA (azidocarbonamide) | Hubriphar | Phase I/II: AIDS
2001, 15:33-45 |
| S1360 | Shionogi Pharmaceuticals | Animal safety data at 9CROI; Human study underway |
| TAK-449 | Takeda
Pharmaceuticals | Company
officials refused request for information |
| T-649 | Trimeris/Roche | Similar to T-1249; paper at 7/01 IAS meeting |
| BMS-806 | Bristol-Myers Squibb | In vitro results at 9CROI; Human trial to start later this year |
| Merck integrase inhibitor | Merck | Phase I studies to commence March 2002 |
| Merck prime-boost vaccine | Merck | Safety trials in HIV-negative volunteers currently underway |
| Missing in Action |
| L-756,423/MK-944A | Merck | Reportedly moving into Phase
II/III; paper at 7CROI |
| AG-1776/JE-2147 | Agouron
(Pfizer) | All
appearances suggest this drug is history. |
| L-708,906, L-731,988 | Merck | Hazuda,
D.J., et al. Science 287(Jan. 28):646 (also, Science News) |
| Didox, Trimodox | Molecules for Health | Ribonucleotide reductase inhibitors -- circa 1995 |
| AOP-RANTES | Gryphon Sciences | Animal (mouse) data only, J Virol 5/99, paper as summer IAS |
| FP-21399 | Lexigen Pharmaceuticals | Bruce
Dezube again: J Infect Dis 2000 182:607-10 |
| PRO2000 | Genetics (formerly Procept) | Being tested as topical microbicide
at Fenway Center |
| HGTV43 | Enzo
Biochem, Inc. | Paper at summer IAS
meeting |
| SJ-3366 | Samjin Pharmaceuticals Ltd. | Paper at 14th Intl.
Conf. on Antiviral Research, 4/01 |
